脑膜瘤[68Ga]Ga-DOTA-TOC PET的药代动力学分析用于评估体内生长抑素受体亚型2
研究纳入15例MRI疑似或复发脑膜瘤患者,术前行动态[68Ga]Ga-DOTA-TOC PET/CT,并与手术标本SSTR2表达进行相关性分析。结果显示多数PET指标与SSTR2蛋白及mRNA显著相关,TBRmean与SSTR2 mRNA相关性最佳(r=0.757,P=0.001)。
要点
- 15例脑膜瘤患者中12例为WHO I级、3例为WHO II级,分级与SSTR2无关联。
- TBRmean与SSTR2 mRNA相关性最佳(r=0.757,P=0.001),SUVmean次之(r=0.714,P=0.003)。
- PET指标与血管生成标志物VEGFA及VB呈正相关,与增殖和炎症无相关性。
核心结论
- 脑膜瘤中[68Ga]Ga-DOTA-TOC的积聚与SSTR2结合及血管化相关,TBRmean是评估SSTR2的最佳PET指标。
研究设计与样本
- 15例MRI疑似或复发脑膜瘤患者术前接受60分钟动态[68Ga]Ga-DOTA-TOC PET/CT,采用可逆两组织室模型加分数血容量(VB)进行动力学建模。
- 术后标本通过免疫组化和/或qPCR测定SSTR2及增殖标志物,通过qPCR测定血管生成和炎症生物标志物。
主要发现
- 组织病理显示12例WHO I级和3例WHO II级脑膜瘤,分级与SSTR2无关联。
- 多数PET指标与SSTR2蛋白显著相关,所有PET指标与SSTR2 mRNA正相关,TBRmean(r=0.757,P=0.001)和SUVmean(r=0.714,P=0.003)相关性最佳。
- [68Ga]Ga-DOTA-TOC PET指标与VEGFA及VB呈显著正相关。
- SSTR2 mRNA与VEGFA呈中度相关(r=0.539,P=0.038)。
- PET指标和SSTR2均与增殖或炎症无相关性。
关键数值与推荐
- TBRmean与SSTR2 mRNA的相关系数r=0.757(P=0.001)。
- SUVmean与SSTR2 mRNA的相关系数r=0.714(P=0.003)。
- SSTR2 mRNA与VEGFA的相关系数r=0.539(P=0.038)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: DOTA-D-Phe1-Tyr3-octreotide with gallium-68 ([68Ga]Ga-DOTA-TOC) is one of the PET tracers that forms the basis for peptide receptor radionuclide therapy based on somatostatin receptor subtype 2 (SSTR2) expression in meningiomas. Yet, the quantitative relationship between [68Ga]Ga-DOTA-TOC accumulation and SSTR2 is unknown. We conducted a correlative analysis of a range of [68Ga]Ga-DOTA-TOC PET metric(s) as imaging surrogate(s) of the receptor binding in meningiomas by correlating the PET results with SSTR2 expression from surgical specimens. We additionally investigated possible influences of secondary biological factors such as vascularization, inflammation and proliferation. METHODS: Fifteen patients with MRI-presumed or recurrent meningiomas underwent a 60-min dynamic [68Ga]Ga-DOTA-TOC PET/CT before surgery. The PET data comprised maximum and mean standardized uptake values (SUVmax, SUVmean) with and without normalization to reference regions, and quantitative measurements derived from kinetic modelling using a reversible two-tissue compartment model with the fractional blood volume (VB). Expressions of SSTR2 and proliferation (Ki-67, phosphohistone-H3, proliferating cell nuclear antigen) were determined by immunohistochemistry and/or quantitative polymerase chain reaction (qPCR), while biomarkers of vascularization (vascular endothelial growth factor A (VEGFA), endothelial marker CD34) and inflammation (cytokine interleukin-18, microglia/macrophage-specific marker CD68) by qPCR. RESULTS: Histopathology revealed 12 World Health Organization (WHO) grade I and three WHO grade II meningiomas showing no link to SSTR2. The majority of [68Ga]Ga-DOTA-TOC PET metrics showed significant associations with SSTR2 protein, while all PET metrics were positively correlated with SSTR2 mRNA with the best results for mean tumour-to-blood ratio (TBRmean) (r = 0.757, P = 0.001) and SUVmean (r = 0.714, P = 0.003). Significant positive correlations were also found between [68Ga]Ga-DOTA-TOC PET metrics, and VEGFA and VB. SSTR2 mRNA was moderately correlated with VEGFA (r = 0.539, P = 0.038). Neither [68Ga]Ga-DOTA-TOC PET metrics nor SSTR2 were correlated with proliferation or inflammation. CONCLUSION: [68Ga]Ga-DOTA-TOC accumulation in meningiomas is associated with SSTR2 binding and vascularization with TBRmean being the best PET metric for assessing SSTR2.
引用
- Bashir A, Vestergaard MB, Binderup T, et al. Pharmacokinetic analysis of [68Ga]Ga-DOTA-TOC PET in meningiomas for assessment of in vivo somatostatin receptor subtype 2. Eur J Nucl Med Mol Imaging. 2020. PMID: 32170347. doi:10.1007/s00259-020-04759-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。